Literature DB >> 20856756

Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice?

Kathryn M Field1, Suzanne Kosmider, Michael Jefford, Ross Jennens, Michael Green, Peter Gibbs.   

Abstract

Treatment options for colorectal cancer have expanded to include multiple oxaliplatin- and irinotecan-based regimens and more biological/targeted therapies.

Entities:  

Year:  2008        PMID： 20856756      PMCID： PMC2793914          DOI： 10.1200/JOP.0852002

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  34 in total

1.  Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

Authors:  F Maindrault-Goebel; C Louvet; T André; E Carola; J P Lotz; J L Molitor; M L Garcia; V Gilles-Amar; V Izrael; M Krulik; A de Gramont
Journal:  Eur J Cancer       Date:  1999-09       Impact factor: 9.162

2.  Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.

Authors:  Howard S Hochster; Axel Grothey; Barrett H Childs
Journal:  J Clin Oncol       Date:  2007-07-30       Impact factor: 44.544

3.  Surveillance following treatment for colorectal cancer in Australia. Has best practice been adopted by medical oncologists?

Authors:  S Kosmider; K Field; M Jefford; R Jennens; P Gibbs
Journal:  Intern Med J       Date:  2008-06       Impact factor: 2.048

4.  A case report of oxaliplatin extravasation.

Authors:  K F Foo; M Michael; G Toner; J Zalcberg
Journal:  Ann Oncol       Date:  2003-06       Impact factor: 32.976

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

6.  Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.

Authors:  E Jäger; M Heike; H Bernhard; O Klein; G Bernhard; D Lautz; J Michaelis; K H Meyer zum Büschenfelde; A Knuth
Journal:  J Clin Oncol       Date:  1996-08       Impact factor: 44.544

7.  Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven Alberts
Journal:  J Clin Oncol       Date:  2006-07-20       Impact factor: 44.544

8.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

Authors:  P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

9.  Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.

Authors:  Laurence Gamelin; Michele Boisdron-Celle; Remy Delva; Véronique Guérin-Meyer; Norbert Ifrah; Alain Morel; Erick Gamelin
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

10.  Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

Authors:  Eduardo Díaz-Rubio; Jose Tabernero; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Manuel Chaves; Alberto Abad; Alfredo Carrato; Bernardo Queralt; Juan José Reina; Joan Maurel; Encarnación González-Flores; Jorge Aparicio; Fernando Rivera; Ferrán Losa; Enrique Aranda
Journal:  J Clin Oncol       Date:  2007-06-04       Impact factor: 44.544
View more
  5 in total

Review 1.  Polymeric nanocarriers: A promising tool for early diagnosis and efficient treatment of colorectal cancer.

Authors:  Mohamed Haider; Khaled Zaki Zaki; Mariam Rafat El Hamshary; Zahid Hussain; Gorka Orive; Haidy Osama Ibrahim
Journal:  J Adv Res       Date:  2021-11-20       Impact factor: 12.822

Review 2.  Targeted nanoparticles for colorectal cancer.

Authors:  Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos
Journal:  Nanomedicine (Lond)       Date:  2016-08-16       Impact factor: 5.307

3.  Dietary glycine decreases both tumor volume and vascularization in a combined colorectal liver metastasis and chemotherapy model.

Authors:  Juste Maneikyte; Augustinas Bausys; Bettina Leber; Angela Horvath; Nicole Feldbacher; Gerald Hoefler; Kestutis Strupas; Philipp Stiegler; Peter Schemmer
Journal:  Int J Biol Sci       Date:  2019-06-04       Impact factor: 6.580

4.  Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis.

Authors:  Sadayuki Kawai; Nozomi Takeshima; Yu Hayasaka; Akifumi Notsu; Mutsumi Yamazaki; Takanori Kawabata; Kentaro Yamazaki; Keita Mori; Hirofumi Yasui
Journal:  BMC Cancer       Date:  2021-02-04       Impact factor: 4.430

5.  Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin.

Authors:  Yueh-Ming Lin; Chih-I Chen; Yi-Ping Hsiang; Yung-Chia Hsu; Kung-Chuan Cheng; Pei-Hsuan Chien; Hsiao-Lin Pan; Chien-Chang Lu; Yun-Ju Chen
Journal:  Int J Mol Sci       Date:  2018-06-14       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.